Navigation Links
New approach for treating recurrent prostate cancer on the horizon

TORONTOA new study shows that an alpha-particle emitting radiopeptideradioactive material bound to a synthetic peptide, a component of proteinis effective for treating prostate cancer in mice, according to researchers at SNM's 56th Annual Meeting in Toronto. The results could eventually result in a significant breakthrough in prostate cancer treatment, especially for patients whose cancer recurs after the prostate is removed.

"Our study shows that this novel form of treatment has the potential to target and destroy cancer cells with minimal damage to surrounding healthy tissue," said Damian Wild, University Hospital Basel, Basel, Switzerland, lead author of the study. "Eventually, this therapy could give hope to some of the hardest-to-treat prostate cancer patients and also could be applied to other types of cancer."

Every year, more than 186,000 men in the United States are newly diagnosed with prostate cancer. The most common types of treatment include surgical removal of some, or all, of the prostate, followed by radiation therapy. More than 30,000 men each year who have had their prostates removed experience recurrence of the cancer. In most of these cases, the disease cannot be localized and treated adequately with conventional treatments; therefore, a systemic treatment that efficiently kills small tumors is needed.

Because tumor cells readily bind with certain peptides, researchers have been able to develop highly specific radiopeptides that bind with tumor cells and treat them using specific therapeutic radioactive substances attached to the radiopeptide. Prostate cancer cellsand many other types of cancer cellshave an overabundance of gastrin-releasing peptide receptors, making the cancer a strong candidate for treatment with radiopeptides.

The study compared two different types of radiopeptides. One group of mice was injected with 213 Bi-DOTA-PESIN, which emits alpha particles that are effective at killing cancer cells. The other group was injected with beta-emitting 177 Lu-DOTA-PESIN, which are also effective in tumor cell-killing, but can also cause damage to nearby healthy cells. Alpha particles are able to kill cancer cells without damaging surrounding healthy tissue. A third group of mice received no treatment.

However, at the maximum tolerated dose, the alpha-emitting 213 Bi-DOTA PESIN was significantly more effective, tripling the survival rate of the mice that received the therapy. The results indicate that the alpha-emitting radiopeptide could provide a new approach for treating prostate cancer and eventually other types of cancer.


Contact: Amy Shaw
Society of Nuclear Medicine

Related medicine news :

1. Health care incentive model offers collaborative approach
2. Free will takes flight: how our brains respond to an approaching menace
3. New approaches to reduce scarring
4. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
5. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
6. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
7. Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness
8. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
9. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
10. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
11. Potential new approach to treat cognitive impairments in schizophrenia
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology: